PHTALOX® Mouthwash as An Option to Reduce Clinical Symptoms of COVID-19: Case Series

Background: The PHTALOX® mouthwash appears in this case series as a promising alternative for reducing the viral load of SARS-CoV-2 and for clinical improvement of infected patients. Objectives: The aim of this study was to report a case series of mouthwash to reduce clinical symptoms in patients diagnosed with COVID-19. Methods: Eight patients used 5ml of PHTALOX® mouthwash for gargling/rinsing during 1 minute/ five times a day during 14 days. Two measurement scales were applied for each patient in different periods to verify sore throat - VAS – Visual Analogic Scale for Pain and the clinical conditions - PS – Performance Status. Results: All patients presented a significant reduction in clinical symptoms with PHTALOX® mouthwash for gargling/rinsing after few days of use, without hospitalization. Conclusion: The PHTALOX® mouthwash protocol appears as a promising alternative for clinical improvement of COVID-19 infected patients. Daily use of this mouthwash rapidly reduced clinical symptoms such as sore throats, coughs and mouth ulcers. Clinical trials are necessary to confirm the effectiveness of PHTALOX® protocol against COVID-19.